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AMD is the major cause of visual loss in individuals older than 50 in the western countries. Whilst tremendous progress has been made by the intraocular repeated injections of anti-VEGFs in wet AMD, no treatment is recognized to prevent progression of dry AMD, which represents more than 50 % of the cases. Interestingly, an over activation of the complement alternative pathway has been associated to both forms of AMD. But, several clinical studies have failed to demonstrate any efficacy of molecules blocking the complement pathway at various stage of its activation. In 2017, another failure was reported with lampalizumab after this drug succeeded in phase 2. Why such failure? What is the exact role of complement in AMD pathogenesis? Is complement regulation a hopeless pathway to follow in AMD? This article summarizes knowledge in the field.